-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 30, Hangzhou Baikai Biopharmaceutical Co.
TROP-2 stands for human trophoblast surface antigen
Due to the high expression of TROP-2 in various solid tumors, it has become a new target for researchers to develop antibody-drug conjugates
According to the press release of Baikai Pharmaceuticals, the company is a biopharmaceutical company focusing on the research and development of new ADC anti-tumor drugs.
References:
[1] BIO-106 IND application for BIO-106, an innovative antibody conjugated drug (ADC) of Baikai Pharmaceuticals, was approved by the US FDA.
Note: The original text has been deleted